PENTIXAPHARM
6.2.2020 12:48:05 CET | Business Wire | Press release
PentixaPharm announced today to have secured € 15 million in a series A financing round led by ELSA Eckert Life Science Accelerator.
PentixaPharm GmbH, a joint venture of Scintomics GmbH and 1717 Life Science Ventures GmbH, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers. Funding is dedicated for a phase II trial of the imaging compound PentixaFor and for a phase I trial of the therapeutic compound PentixaTher in Central Nervous System (CNS) Lymphoma while supporting proof-of-concept studies in various other indications.
Interviews:
“With the renowned expertise of the PentixaPharm team, the company is well positioned to bring the lead-compounds PentixaFor and PentixaTher with an effective clinical development program to the next level. We are thrilled to accompany this venture.”,
says Phillip Eckert, Responsible Programme Manager and Partner at ELSA.
“Scintomics is very excited about this new partnership marking another important milestone towards a strong positioning of PentixaPharm as radiopharmaceutical development specialist” , comments Saskia Kropf, CEO of Scintomics. Prof. Hans-Jürgen Wester, founder of Scintomics, adds: “We are enthusiastic by this round A financing to advance the CXCR4 program. Preclinical and clinical data so far have demonstrated encouraging evidence and good potential for targeted cancer therapies. Now with the experienced development team of PentixaPharm, we are sure to quickly establish this theranostic approach towards meaningful clinical trials.”
“We are delighted that in ELSA we have found a strong financing partner with an outstanding expertise in the radiopharmaceutical field. The proceeds of the series A financing will enable us to bring a new treatment for CNS Lymphoma, up to today a disease with limited treatment options, a little closer to patients in need”, adds Anna Steeger, Co-founder of 1717 LSV GmbH and CEO of PentixaPharm.
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The [68 Ga]Gallium based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukemia, lymphoma, and multiple myeloma – but also for solid tumors like adrenocortical carcinoma and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke can be visualised with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About ELSA Eckert Life Science Accelerator
ELSA, a subsidiary of Eckert Wagniskapital und Frühphasenfinanzierung, is a Berlin-based life science incubator with over two decades of experience in the venture capital industry. ELSA invests primarily in start-up companies, which are in need of first-round venture capital financing and actively supports them during the transformation process from start-ups into mature companies.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalised cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200206005461/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NIQ and Ogury Collaborate to Enhance Media Planning and Audience Strategy with GeoPurchase Insights18.6.2026 12:00:00 CEST | Press release
New initiative brings real-world retail purchase signals into Ogury’s Persona Intelligence Engine to deliver deeper, privacy preserving insights across North America and Europe NIQ (NYSE: NIQ), the world’s leading consumer intelligence company, today announced a new collaboration with Ogury, the global AdTech company powered by Persona Intelligence. Through the collaboration, Ogury will integrate NIQ’s GeoPurchase data into its Persona Intelligence Engine, strengthening audience planning, media activation, and strategic insights for marketers. NIQ delivers world-leading retail intelligence, capturing actual purchase data at the product level across key retailers around the world. Through this collaboration, NIQ is providing GeoPurchase insights at scale across France, Germany, Spain, Italy, the UK, as well as the United States and Canada, bringing a new layer of real-world retail purchase behavior into Ogury’s Persona Intelligence Engine. Combined with Ogury’s audience-first data model
Linvo Sets Sights on AI-Led Wealth Management, Opens AI Advisor Roles for 202618.6.2026 11:40:00 CEST | Press release
Linvo AG, a Zurich-based multi-family office and wealth management firm, today set out its vision for the year ahead, naming applied artificial intelligence as the centre of its strategy for 2026 and opening a new set of AI advisor roles to deliver it. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618933521/en/ Linvo sets sights on AI-led wealth management, opens AI advisor roles for 2026 The firm sees the coming year as the point at which AI moves from a support tool to a core discipline within wealth management — shaping how portfolios are analysed, how clients are served, and how advisory teams spend their time. The new AI advisor roles are intended to anchor that shift inside the firm. "2026 is the year we stop treating AI as an add-on and start treating it as a discipline in its own right," said Alexander Kogan, Director at Linvo. "Hiring AI advisors is how we build that future deliberately, rather than leaving it t
Frost & Sullivan 2026 Technology Innovation Leadership Best Practices Recognition for Ohmium International18.6.2026 10:31:00 CEST | Press release
Ohmium International Inc., a leading manufacturer of cutting-edge, high-efficiency, and modular Proton Exchange Membrane (PEM) electrolyzers, has received the 2026 Global Technology Innovation Leadership Recognition for Best Practices in the PEM electrolyzer and green hydrogen industry by Frost & Sullivan. This recognition highlights Ohmium's continued advancement of cutting-edge PEM technology into scalable, real-world hydrogen solutions that address critical energy and industrial challenges across global markets. Each year, Frost & Sullivan presents the Technology Innovation Leadership Recognition for Best Practices to organizations that demonstrate exceptional achievement in leveraging technology to drive market transformation and measurable business impact. The firm evaluates companies across two core dimensions: technology leverage and business impact. Ohmium excelled across both measures, demonstrating commitment to innovation, stage gate efficiency, commercialization, and applic
Infobip Ranked in Top 25 of Fortune's Europe's Most Innovative Companies 202618.6.2026 10:11:00 CEST | Press release
A strong result highlighting Infobip’s momentum in European tech innovation Global AI-first cloud communications platform Infobip has been ranked in the top 25 of Fortune's Europe's Most Innovative Companies 2026, marking a strong rise on this year's list. The announcement was made at VivaTech in Paris. Last year, Infobip entered Fortune's inaugural ranking at number 68. This year, it climbs to 16! The Fortune Europe's Most Innovative Companies list, in partnership with the global research firm Statista, evaluates companies based on innovation culture, product development, and process improvements. Infobip's rise reflects the accelerating momentum behind its AI-first strategy, including the launch of Infobip AgentOS, its AI-native fully managed solution that orchestrates autonomous AI-driven customer journeys at scale. Infobip's innovation credentials are further reinforced by its role in Important Project of Common European Interest (IPCEI) for Next Generation Cloud Infrastructure and
Philip Morris International Announces New Regional Leadership18.6.2026 10:00:00 CEST | Press release
The appointments strengthen the company’s leadership pipeline as it moves towards a smoke‑free future Philip Morris International (PMI) (NYSE: PM) announced a series of regional leadership appointments that support its ongoing shift toward a smoke‑free future. Effective August 1, 2026, Marco Hannappel has been appointed President, Europe Region, and Can Kuterdem has been appointed President, Latin America & Canada Region. These appointments build on PMI’s evolved organizational model announced in late 2025, under which Gijs de Best serves as President, South Asia, Indochina, CIS & Middle East & Africa Region, and Vassilis Gkatzelis continues as President East & Southeast Asia, Pacific and PMI Global Travel Retail Region. The four regional presidents report to Frederic de Wilde - CEO of the International Business Unit of PMI and are the key operational leaders for the unit that generates the large majority of total PMI net revenues. Marco Hannappel takes over the role of President, Euro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom